AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28169285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1394
Study 25833348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 30
Study 25833348 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Number of subjects: 30
Study 25833348 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 23597528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate monohydrate (MFM)
Number of subjects: 94
Study 23597528 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 94
Study 21819564 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year Disease Management Programme (DMP) led by a case manager
Number of subjects: 700
Study 21819564 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700
Study 19887582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum cholesterol (<200 mg/dL)
Number of subjects: 5586
Study 19887582 — intervention group
Group type: COMPARATOR
Intervention: High serum cholesterol (>=200 mg/dL)
Number of subjects: 5586
Study 17950802 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-assay B-type natriuretic peptide (BNP)
Number of subjects: 141
Study 17950802 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I
Number of subjects: 141
Study 17950802 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-derived hemodynamics
Number of subjects: 141
Study 15128632 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia + General anesthesia (EP group)
Number of subjects: 40
Study 15128632 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA group)
Number of subjects: 40
Study 11502935 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated inclusion body myositis (IBM)
Number of subjects: 11
Study 9926771 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated implants that were mobile at placement
Number of subjects: 81
Study 9926771 — intervention group
Group type: COMPARATOR
Intervention: Non-HA-coated implants that were mobile at placement
Number of subjects: 81
Study 9926771 — intervention group
Group type: EXPERIMENTAL
Intervention: All implants (mobile or immobile) that integrated
Number of subjects: 81
Study 9926771 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated implants (mobile)
Number of subjects: 81
Study 9926771 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated implants (immobile)
Number of subjects: 81
Study 9926771 — intervention group
Group type: COMPARATOR
Intervention: Non-HA-coated implants
Number of subjects: 81
Study 7953212 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual instruction
Number of subjects: 75
Study 7953212 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 75
Study 7953212 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders
Number of subjects: 75
Study 7953212 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational material or group education combined with feedback
Number of subjects: 75
Study 7953212 — intervention group
Group type: EXPERIMENTAL
Intervention: All combinations with individual instruction
Number of subjects: 75
Study 7953212 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review and feedback
Number of subjects: 75
Study 2683172 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative blood transfusion in stage I breast cancer patients
Number of subjects: 812
Study 2683172 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative blood transfusion in stage II breast cancer patients
Number of subjects: 812
Study 791038 — intervention group
Group type: EXPERIMENTAL
Intervention: ethyl linoleate agent (hELate) applied at a dose of 25 mg/kg only once after burn
Number of subjects: 60
Study 31277797 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept every 6 weeks
Number of subjects: 40
Study 31277797 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept treat-and-adjust
Number of subjects: 40
Study 31277797 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study 28829204 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 0.8 mg/kg
Number of subjects: 0
Study 28829204 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study 28829204 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab and Methotrexate
Number of subjects: 0
Study 22573729 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cigarette smokers
Number of subjects: 143
Study 22573729 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 143
Study 22573729 — intervention group
Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 143
Study 22573729 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers and former smokers
Number of subjects: 143
Study 21051423 — intervention group
Group type: EXPERIMENTAL
Intervention: Point 4 injection technique (Group A)
Number of subjects: 48
Study 21051423 — intervention group
Group type: COMPARATOR
Intervention: 2-point injection technique (Group B)
Number of subjects: 48
Study 19597031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg/d
Number of subjects: 235
Study 19597031 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide 200 mg/d
Number of subjects: 235
Study 19597031 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tamoxifen and fenretinide
Number of subjects: 235
Study 19597031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 19597031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 235
Study 19597031 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 235
Study 16570888 — intervention group
Group type: EXPERIMENTAL
Intervention: CellTrans blood salvage device (group A, 32 patients)
Number of subjects: 49
Study 16570888 — intervention group
Group type: COMPARATOR
Intervention: Redivac high vacuum drainage system (group B, 17 patients)
Number of subjects: 49
Study 16570888 — intervention group
Group type: EXPERIMENTAL
Intervention: CellTrans blood salvage device (group A)
Number of subjects: 49
Study 15617460 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 60
Study 15617460 — intervention group
Group type: COMPARATOR
Intervention: Perindopril 4 mg
Number of subjects: 60
Study 11317092 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for physicians and nursing home staff
Number of subjects: 147
Study 11317092 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 147
Study 8988819 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms.kg‐1 sufentanil
Number of subjects: 34
Study 8988819 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms.kg‐1 sufentanil
Number of subjects: 34
Study 8265321 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines (AC)
Number of subjects: 240
Study 8265321 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell pertussis vaccines (WC)
Number of subjects: 240
Study 8265321 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines (AC) containing filamentous hemagglutinin (FHA)
Number of subjects: 240
Study 8265321 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocomponent PT vaccine
Number of subjects: 240
Study 3103662 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow (FGF) of 70 ml kg‐1 min‐1
Number of subjects: 32
Study 3103662 — intervention group
Group type: COMPARATOR
Intervention: Fresh gas flow (FGF) of 100 ml kg‐1 min‐1
Number of subjects: 32
Study 31348051 — intervention group
Group type: EXPERIMENTAL
Intervention: BUHE intubation position
Number of subjects: 138
Study 31348051 — intervention group
Group type: COMPARATOR
Intervention: GLSC laryngoscopy
Number of subjects: 138
Study 28883225 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (2.5 mg/5 mg/20 mg)
Number of subjects: 360
Study 27295199 — intervention group
Group type: EXPERIMENTAL
Intervention: High motivated performance (HMP) condition
Number of subjects: 42
Study 27295199 — intervention group
Group type: COMPARATOR
Intervention: Low motivated performance (LMP) condition
Number of subjects: 42
Study 25328464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic bearing system
Number of subjects: 28
Study 23363386 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine administration with breakfast
Number of subjects: 45
Study 23363386 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine administration while fasting
Number of subjects: 45
Study 23363386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (with breakfast and fasting)
Number of subjects: 45
Study 19692379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy without ILM peeling
Number of subjects: 74
Study 19692379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with 0.05% isotonic ICG‐assisted ILM peeling
Number of subjects: 74
Study 19692379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with 0.15% trypan blue‐assisted ILM peeling
Number of subjects: 74
Study 19692379 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 74
Study 18418719 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic electrical bioimpedance (TEB) cardiac output (CO) measured using NICOMON (Larsen & Toubro Ltd. India)
Number of subjects: 35
Study 18418719 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution (Td) cardiac output (CO) measured using a PAC
Number of subjects: 35
Study 15919144 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure OCD participants
Number of subjects: 0
Study 15919144 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid OCD + TS participants
Number of subjects: 0
Study 14504060 — intervention group
Group type: EXPERIMENTAL
Intervention: palonosetron 0.25 mg
Number of subjects: 570
Study 14504060 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 32 mg
Number of subjects: 570
Study 10893654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate (E-4018) 50 mg
Number of subjects: 0
Study 10893654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate (E-4018) 100 mg
Number of subjects: 0
Study 10893654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate (E-4018) 150 mg
Number of subjects: 0
Study 10893654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8867253 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 55
Study 8867253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 55
Study 8867253 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 55
Study 1637761 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed-results group
Number of subjects: 1000
Study 1637761 — intervention group
Group type: COMPARATOR
Intervention: Withheld-results group
Number of subjects: 1000
Study 4022214 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (600 mg daily for 30 days)
Number of subjects: 30
Study 30585769 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive Low-Glucose Management (PLGM) system
Number of subjects: 8523
Study 30585769 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8523
Study 30285823 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education program delivered by teachers at schools for Intermediate Vocational Education.
Number of subjects: 1820
Study 30285823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no web-based program).
Number of subjects: 1820
Study 30285823 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education program.
Number of subjects: 1820
Study 27282502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondepressed group
Number of subjects: 430
Study 27282502 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed group
Number of subjects: 430
Study 25247929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric‐carboxymaltose (2 ml, 100 mg)
Number of subjects: 14
Study 25247929 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (PLACEBO)
Number of subjects: 14
Study 21878454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex (nabiximols)
Number of subjects: 36
Study 21878454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20007337 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed bread (25 g of flaxseed, 46 mg lignans)
Number of subjects: 38
Study 20007337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (wheat bran, <1 mg lignans)
Number of subjects: 38
Study 20007337 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed bread
Number of subjects: 38
Study 20007337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 17409026 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactor intervention program
Number of subjects: 0
Study 16846682 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream
Number of subjects: 10
Study 16846682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber gloves
Number of subjects: 10
Study 16846682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber gloves plus respirator
Number of subjects: 10
Study 16846682 — intervention group
Group type: COMPARATOR
Intervention: No personal protective equipment
Number of subjects: 10
Study 12792350 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of tenofovir DF once daily
Number of subjects: 189
Study 10858988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized A. simplex larvae (1, 5, or 25 larvae) or lyophilized antigen
Number of subjects: 12
Study 10858988 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 12
Study 10858988 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival provocation tests
Number of subjects: 12
Study 8856395 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (36% energy as protein)
Number of subjects: 8
Study 8856395 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (15% energy as protein, high in carbohydrate)
Number of subjects: 8
Study 8856395 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (15% energy as protein, high in fat)
Number of subjects: 8
Study 1847127 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction regimen of external beam radiotherapy to the liver (21.0 Gy, 3.0 Gy/Fx, 10 MV photons, 4 days per week) with low-dose chemotherapy (5-Fluorouracil (FU), 500 mg, i.v.; Doxorubicin, 15 mg, i.v.) on treatment Days 1, 3, 5 and 7.
Number of subjects: 216
Study 1847127 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy as hyperfractionated treatment (1.2 Gy twice daily, 4 hours separation, 5 days per week, 24.0 Gy total) with similar chemotherapy.
Number of subjects: 216
Study 1847127 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction regimen with cycles of radiolabeled antibody therapy (30 mCi I-131 antiferritin, Day 0, and 20 mCi, Day 5).
Number of subjects: 216
Study 1847127 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Score (KPS) (80-100 vs. less than 80).
Number of subjects: 216
Study 1847127 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence/absence of ascites.
Number of subjects: 216
Study 1847127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin level (less than 1.5 vs. greater than or equal to 1.5).
Number of subjects: 216
Study 1847127 — intervention group
Group type: EXPERIMENTAL
Intervention: SGOT (less than or equal to 35 vs. greater than 35).
Number of subjects: 216
Study 1847127 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase (less than or equal to 95 vs. greater than 95).
Number of subjects: 216
Study 1847127 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP status stratification.
Number of subjects: 216
Study 6338063 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 6
Study 6338063 — intervention group
Group type: COMPARATOR
Intervention: Sham‐plasmapheresis
Number of subjects: 6
Study 31113194 — intervention group
Group type: EXPERIMENTAL
Intervention: European Randomized study of Screening for Prostate Cancer calculator (ERSPC)
Number of subjects: 195
Study 31113194 — intervention group
Group type: COMPARATOR
Intervention: Prostate specific antigen (PSA)
Number of subjects: 195
Study 28711119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bias reduction (avoid food stimulus) group
Number of subjects: 0
Study 28711119 — intervention group
Group type: COMPARATOR
Intervention: Bias enhancement (attend to food stimulus) group
Number of subjects: 0
Study 26066932 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed warnings
Number of subjects: 682
Study 26066932 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed warnings
Number of subjects: 682
Study 26066932 — intervention group
Group type: COMPARATOR
Intervention: Control warning (text-only based on FDA-required warnings)
Number of subjects: 682
Study 23629867 — intervention group
Group type: EXPERIMENTAL
Intervention: Real H-coil rTMS
Number of subjects: 25
Study 23629867 — intervention group
Group type: COMPARATOR
Intervention: Sham H-coil rTMS
Number of subjects: 25
Study 21457677 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 234
Study 21457677 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 234
Study 21457677 — intervention group
Group type: COMPARATOR
Intervention: < 25% improvement in YMRS score
Number of subjects: 234
Study 21457677 — intervention group
Group type: COMPARATOR
Intervention: < 50% improvement in YMRS score
Number of subjects: 234
Study 19586218 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource workshop
Number of subjects: 218
Study 19586218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no resource workshop)
Number of subjects: 218
Study 17371886 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate, 70 mg once weekly
Number of subjects: 112
Study 17371886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 15605615 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 22
Study 15605615 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 22
Study 11732382 — intervention group
Group type: COMPARATOR
Intervention: tenoxicam 40 mg intravenously (i.v.)
Number of subjects: 60
Study 11732382 — intervention group
Group type: COMPARATOR
Intervention: tenoxicam 40 mg intramuscularly (i.m.)
Number of subjects: 60
Study 11732382 — intervention group
Group type: COMPARATOR
Intervention: piroxicam 40 mg intramuscularly (i.m.)
Number of subjects: 60
Study 11732382 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo
Number of subjects: 60
Study 9218667 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped‐care antihypertensive drug therapy (chlorthalidone 12.5-25 mg or matching placebo, atenolol 25-50 mg or matching placebo)
Number of subjects: 4736
Study 9218667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study 9218667 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped‐care antihypertensive drug therapy (for patients with prior MI)
Number of subjects: 4736
Study 7970063 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin-TP5 in addition to antibiotic prophylaxis
Number of subjects: 50
Study 7970063 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy alone
Number of subjects: 50
Study 3121487 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (50 micrograms i.v.)
Number of subjects: 15
Study 3121487 — intervention group
Group type: EXPERIMENTAL
Intervention: DOM (5 mg/h infusion)
Number of subjects: 15
Study 3121487 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (50 micrograms i.v.) plus DOM (5 mg/h i.v.)
Number of subjects: 15
Study 3121487 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 15
Study 29974278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (OK + atropine 0.01% ophthalmic solution)
Number of subjects: 40
Study 29974278 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy group (OK)
Number of subjects: 40
Study 27001471 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (tablet containing 20 mg of lactoferrin, 2.6 mg of lactoperoxidase, and 2.6 mg of glucose oxidase)
Number of subjects: 39
Study 27001471 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo tablet)
Number of subjects: 39
Study 25461790 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help CBT-I with telephone support (SHS)
Number of subjects: 312
Study 25461790 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help CBT-I (SH)
Number of subjects: 312
Study 25461790 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list (WL)
Number of subjects: 312
Study 23876539 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol plus perivascular vasopressin
Number of subjects: 50
Study 23876539 — intervention group
Group type: COMPARATOR
Intervention: Perivascular vasopressin alone
Number of subjects: 50
Study 20047707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 0
Study 20047707 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18484507 — intervention group
Group type: EXPERIMENTAL
Intervention: PLRA treatment (+1.00D reading addition)
Number of subjects: 24
Study 18484507 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical flipper treatment (+/‐ 1.50D)
Number of subjects: 24
Study 16556541 — intervention group
Group type: EXPERIMENTAL
Intervention: Three near zero-order controlled-release pseudoephedrine hydrochloride formulations
Number of subjects: 10
Study 16556541 — intervention group
Group type: EXPERIMENTAL
Intervention: Three formulations
Number of subjects: 10
Study 12968857 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial taping
Number of subjects: 71
Study 12968857 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral taping
Number of subjects: 71
Study 12968857 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral taping
Number of subjects: 71
Study 12968857 — intervention group
Group type: COMPARATOR
Intervention: Untaped condition
Number of subjects: 71